Search This Blog

Thursday, May 4, 2023

Tonix: IND OKd for Preventive for Rejection in Kidney Transplant

 Multiple Additional Indications Possible, Including Autoimmune Diseases: Pipeline within a Product

Published Non-Human Primate Studies Show TNX-1500 Prolongs Renal and Heart Allograft Survival

Phase 1 Clinical Trial of TNX-1500 Expected to Start Third Quarter 2023

https://www.biospace.com/article/releases/tonix-pharmaceuticals-announces-ind-clearance-for-tnx-1500-anti-cd40l-mab-for-the-prevention-of-organ-rejection-in-patients-receiving-a-kidney-transplant/

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)